McK6A1
McK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases[1].
Product Specifications
UNSPSC
12352209
Target
Amyloid-β
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Smiles
N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCCC[C@@H](C(NNC(C1=CC(NC(C(N[C@H](C(N[C@H]2CC3=CC=C(O)C=C3)=O)CCCCN)=O)=O)=CC=C1OC)=O)=O)N)=O)CCCCN)=O)CC4=CC=C(O)C=C4)=O)CC5=CNC6=CC=CC=C56)=O)CC(C)C)=O)[C@@H](C)O)=O)CCCNC2=O
Molecular Formula
C71H99N17O16
Molecular Weight
1446.65
References & Citations
[1]Lu J, et al., Structure-Based Peptide Inhibitor Design of Amyloid-β Aggregation. Front Mol Neurosci. 2019 Mar 4;12:54.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS7069028 Inquire
Recombinant Streptococcus pneumoniae Protease HtpX homolog (htpX), partial
Ask
View Details 